
### [NCIT:C8936](http://purl.obolibrary.org/obo/NCIT_C8936)
**Label:** B Lymphoblastic Leukemia/Lymphoma

**Subclasses:** [NCIT:C8937](http://purl.obolibrary.org/obo/NCIT_C8937) (Stage II B Lymphoblastic Lymphoma), [NCIT:C7209](http://purl.obolibrary.org/obo/NCIT_C7209) (Childhood B Lymphoblastic Lymphoma), [NCIT:C80326](http://purl.obolibrary.org/obo/NCIT_C80326) (B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified), [NCIT:C80347](http://purl.obolibrary.org/obo/NCIT_C80347) (B Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)), [NCIT:C80346](http://purl.obolibrary.org/obo/NCIT_C80346) (B Acute Lymphoblastic Leukemia with t(5;14)(q31.1;q32.3); IL3-IGH), [NCIT:C80345](http://purl.obolibrary.org/obo/NCIT_C80345) (Hypodiploid B Acute Lymphoblastic Leukemia), [NCIT:C45241](http://purl.obolibrary.org/obo/NCIT_C45241) (Cutaneous B Lymphoblastic Leukemia/Lymphoma), [NCIT:C80344](http://purl.obolibrary.org/obo/NCIT_C80344) (Hyperdiploid B Acute Lymphoblastic Leukemia), [NCIT:C80343](http://purl.obolibrary.org/obo/NCIT_C80343) (B Acute Lymphoblastic Leukemia with t(12;21)(p13.2;q22.1); ETV6-RUNX1), [NCIT:C80342](http://purl.obolibrary.org/obo/NCIT_C80342) (B Acute Lymphoblastic Leukemia with t(v;11q23.3); KMT2A Rearranged), [NCIT:C8872](http://purl.obolibrary.org/obo/NCIT_C8872) (Stage III B Lymphoblastic Lymphoma), [NCIT:C8873](http://purl.obolibrary.org/obo/NCIT_C8873) (Stage IV B Lymphoblastic Lymphoma), [NCIT:C8870](http://purl.obolibrary.org/obo/NCIT_C8870) (Refractory B Lymphoblastic Lymphoma), [NCIT:C8871](http://purl.obolibrary.org/obo/NCIT_C8871) (Stage I B Lymphoblastic Lymphoma), [NCIT:C9143](http://purl.obolibrary.org/obo/NCIT_C9143) (Adult B Acute Lymphoblastic Leukemia), [NCIT:C80328](http://purl.obolibrary.org/obo/NCIT_C80328) (B Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities), [NCIT:C128629](http://purl.obolibrary.org/obo/NCIT_C128629) (B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative), [NCIT:C68659](http://purl.obolibrary.org/obo/NCIT_C68659) (Childhood B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1), [NCIT:C80341](http://purl.obolibrary.org/obo/NCIT_C80341) (B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)), [NCIT:C80340](http://purl.obolibrary.org/obo/NCIT_C80340) (B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH), [NCIT:C80338](http://purl.obolibrary.org/obo/NCIT_C80338) (B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy), [NCIT:C8869](http://purl.obolibrary.org/obo/NCIT_C8869) (Recurrent B Lymphoblastic Lymphoma), [NCIT:C80335](http://purl.obolibrary.org/obo/NCIT_C80335) (B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy), [NCIT:C80334](http://purl.obolibrary.org/obo/NCIT_C80334) (B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1), [NCIT:C8868](http://purl.obolibrary.org/obo/NCIT_C8868) (B Lymphoblastic Lymphoma), [NCIT:C80332](http://purl.obolibrary.org/obo/NCIT_C80332) (B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged), [NCIT:C80331](http://purl.obolibrary.org/obo/NCIT_C80331) (B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1), [NCIT:C7338](http://purl.obolibrary.org/obo/NCIT_C7338) (Adult B Lymphoblastic Lymphoma), [NCIT:C8644](http://purl.obolibrary.org/obo/NCIT_C8644) (B Acute Lymphoblastic Leukemia), [NCIT:C7310](http://purl.obolibrary.org/obo/NCIT_C7310) (Splenic B Lymphoblastic Lymphoma), [NCIT:C9140](http://purl.obolibrary.org/obo/NCIT_C9140) (Childhood B Acute Lymphoblastic Leukemia), [NCIT:C114819](http://purl.obolibrary.org/obo/NCIT_C114819) (Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1), [NCIT:C36312](http://purl.obolibrary.org/obo/NCIT_C36312) (B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1), 

**Class expressions from DL-Learner:**

- Thing 53.75%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39957](http://purl.obolibrary.org/obo/NCIT_C39957) (Epididymal Adenocarcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39956](http://purl.obolibrary.org/obo/NCIT_C39956) (Rete Testis Adenoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3994](http://purl.obolibrary.org/obo/NCIT_C3994) (Stage IV Colon Cancer AJCC v6))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3993](http://purl.obolibrary.org/obo/NCIT_C3993) (Stage II Colon Cancer AJCC v6))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39914](http://purl.obolibrary.org/obo/NCIT_C39914) (Gain of Chromosome 12p))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3991](http://purl.obolibrary.org/obo/NCIT_C3991) (Thrombocytopenia Due to Immune Destruction))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39909](http://purl.obolibrary.org/obo/NCIT_C39909) (Gain of Chromosome 18q))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39901](http://purl.obolibrary.org/obo/NCIT_C39901) (Prostatic Duct Urothelial Carcinoma))) 37.63%


